[1] ZIAEIN B,FONAROW G C.Epidemiology and aetiology of heart failure[J].Nat Rev Cardiol,2016,13(6):368-378.
[2] POCOEK S J,WANG D,PFEFFER M A,et al.Predictors of mortality and morbidity in patients with chronic heart failure[J].Eur Heart J,2006,27(1):65-75.
[3] MCALISTER F A,WIEBE N,EZEKOWITZ J A,et al.Meta-analysis:beta-blocker dose,heart rate reduction,and death in patients with heart failure[J].Ann Interu Med,2009,150(1):784-794.
[4] KOMAJDA M,FOLLATH F,SWEDBERG K,et al.The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe.Part 2:treatnlent[J].Eur Heart J,2003,24:464-474.
[5] FLANNERY G,GEHFIG-MILLS R,BILLAH B,et al.Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers[J].Am J Cardiol,2008,101(6):865-869.
[6] MAJEWSKI S,SLOMKA S,ZIELINSKA-WYDERKIEWICZ E,et al.Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obslructive airway disease:a randomized,doubleblind,placebo-conlrolled,crossover study[J].Am J Cardiovasc Drugs,2012,12(3):179-188.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[8] ATS Committee on proficiency Standards for Clinical Pulmonary Function Laboratories.ATS statement:guidelines for the six-minute walk test[J].Am J Respir Crit Care Med,2002,166(1):111-117.
[9] SWEDBERG K,KOMAJDA M,BHM M,et al.Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study[J].Lancet,2010,376(9744):875-885.
[10] 张明惠.新型控制心率药物伊伐布雷定临床应用研究进展[J].临床荟萃,2011,26(21):1919-1921.
[11] FOX K,FORD I,STEG P G,et al.Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):a randomized,double-blind,placebo-controlled trial[J].Lancet,2008,372(9641):807-816.
[12] SAVARESE G,TRIMAREO B,DELLEGROTTAGLIE S,et al.Natriuretic peptide-guided therapy in chronic heart failure:a meta-analysis of 2686 patients in 12 randomized trials[J].PLoS One,2013,8(3):e58287.
[13] 陈雄,崔俊友,李健.慢性心力衰竭患者血浆脑钠肽浓度与体质量指数的相关性[J].东南大学学报(医学版),2012,31(2):199-201.
[14] GRUSON D,LEPOUTRE T,AHN S A,et al.Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction[J].Int J Cardiol,2014,172(1):e250-252.
[15] 杨巧梅,梁玉芝,杨威,等.伊伐布雷定延长离体心脏单相动作电位时程及其致心律失常作用[J].中国循环杂志,2015,30(6):585-589.
[16] 黄文凤,余剑波,刘敏,等.伊伐布雷定联合比索洛尔对冠心病PCI术后患者心脏康复的影响[J].中国医院药学杂志,2017,37(2):151-154.
[17] 赵玉清,袁桂莉,张进顺,等.和肽素联合N末端B型利钠肽原评估慢性心力衰竭患者预后的价值[J].中国循环杂志,2014,29(4):275-278. |